GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anxo Pharmaceutical Co Ltd (ROCO:6677) » Definitions » Net Income From Continuing Operations

Anxo Pharmaceutical Co (ROCO:6677) Net Income From Continuing Operations : NT$54.4 Mil (TTM As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Anxo Pharmaceutical Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Anxo Pharmaceutical Co's net income from continuing operations for the six months ended in Jun. 2023 was NT$11.7 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2023 was NT$54.4 Mil.

Anxo Pharmaceutical Co Net Income From Continuing Operations Historical Data

The historical data trend for Anxo Pharmaceutical Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anxo Pharmaceutical Co Net Income From Continuing Operations Chart

Anxo Pharmaceutical Co Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.12 29.41 48.91 24.33 -4.71

Anxo Pharmaceutical Co Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.66 20.66 -47.42 42.71 11.69

Anxo Pharmaceutical Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$54.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anxo Pharmaceutical Co (ROCO:6677) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anxo Pharmaceutical Co Ltd (ROCO:6677) » Definitions » Net Income From Continuing Operations
Comparable Companies
TPE:1731 ROCO:4172 ROCO:6539 ROCO:8432 ROCO:1796 TPE:3054 ROCO:6817 ROCO:4120 ROCO:1780 ROCO:4747 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
8th Floor-3, Nanjing East Road, No. 206, Section 2, Taipei City, TWN
Website
http://www.anxo.com.tw
Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.

Anxo Pharmaceutical Co (ROCO:6677) Headlines

No Headlines